Do we need a change in surgical antimicrobial prophylaxis? Insights from Dr. Camilla Rodrigues

Do we need a change in surgical antimicrobial prophylaxis? Insights from Dr. Camilla Rodrigues

2025.04.22
Antimicrobial resistance (AMR) continues to pose a serious threat to global health systems, particularly in high-burden countries like India. The challenges it presents to surgical treatment are complex and evolving, demanding both robust surveillance and strategic preventive interventions. In this interview, Dr. Camilla Rodrigues from Hinduja Hospital shares the current epidemiological landscape of AMR in India, discusses the risks it poses to surgical patients, and outlines successful approaches her center has implemented to mitigate these threats—particularly through systematic MRSA decolonization and strengthened infection control protocols.
CSCO BC Guidelines | Prof. Ying Yan: Precision Diagnosis and Tailored Therapy — Treatment Updates for HER2-Low and Ultra-Low Breast Cancer

CSCO BC Guidelines | Prof. Ying Yan: Precision Diagnosis and Tailored Therapy — Treatment Updates for HER2-Low and Ultra-Low Breast Cancer

2025.04.22
The 2025 National Breast Cancer Conference, held in Beijing from April 11 to 13, introduced significant updates to the 2025 edition of the CSCO Breast Cancer Guidelines (CSCO BC Guidelines). Among the most notable changes was a revision in the treatment approach for patients with HER2-low breast cancer. Oncology Frontier invited Professor Ying Yan from Beijing Cancer Hospital to provide insights into the new treatment strategies for HER2-low and HER2 ultra-low breast cancer.
ELCC Co-Chair, Professor Enrico Ruffini Highlights Key Differences in Surgical Management Strategies for Thymoma and Thymic Carcinoma

ELCC Co-Chair, Professor Enrico Ruffini Highlights Key Differences in Surgical Management Strategies for Thymoma and Thymic Carcinoma

2025.04.22
At the 2025 European Lung Cancer Congress (ELCC), Professor Enrico Ruffini, thoracic surgeon at the Università di Torino and Co-Chair of the ELCC, delivered a dedicated presentation titled "Thymoma and thymic carcinoma: Different surgical management strategies?" During the conference, Oncology Frontier had the opportunity to speak with Professor Ruffini for an in-depth discussion on the latest developments in surgical treatment for thymic tumors and key takeaways from the ELCC.
In-Depth Dialogue with the Chief Medical Officer: Defining AI Boundaries, Breaking Through Resource Equity, and Addressing Professional Burnout

In-Depth Dialogue with the Chief Medical Officer: Defining AI Boundaries, Breaking Through Resource Equity, and Addressing Professional Burnout

2025.04.21
As the 2025 Annual Meeting of the National Comprehensive Cancer Network (NCCN) concluded, Oncology Frontier exclusively interviewed Dr. Wui-Jin Koh, Chief Medical Officer of NCCN, to decode the future trends in cancer care. From the application prospects of AI-assisted medical decision-making to the inclusive practice of decentralized clinical trials, from the systemic challenges of combating healthcare professionals' burnout to the ecological reconstruction of cancer patient care systems, Dr. Wui-Jin Koh’s insights not only reveal NCCN’s future directions but also provide valuable references for the global medical community.
ELCC 2025 | Professor Rui Ma on the Final OS Results from the MARIPOSA Study

ELCC 2025 | Professor Rui Ma on the Final OS Results from the MARIPOSA Study

2025.04.20
The 2025 European Lung Cancer Congress (ELCC) officially opened on March 26 in Paris, France. On the very first day, during the Proffered Paper Session 1, the highly anticipated final overall survival (OS) results from the MARIPOSA study (Abstract 4O) were presented.Oncology Frontier invited Professor Rui Ma of Liaoning Cancer Hospital to provide an in-depth expert analysis of the updated data and its implications for clinical practice.